000007089 001__ 7089
000007089 005__ 20210129210433.0
000007089 0247_ $$2pmid$$apmid:20870148
000007089 0247_ $$2DOI$$a10.1016/j.nucmedbio.2010.04.185
000007089 0247_ $$2WOS$$aWOS:000282803500001
000007089 0247_ $$2ISSN$$a1872-9414
000007089 0247_ $$2altmetric$$aaltmetric:7408224
000007089 037__ $$aPreJuSER-7089
000007089 041__ $$aeng
000007089 082__ $$a610
000007089 084__ $$2WoS$$aRadiology, Nuclear Medicine & Medical Imaging
000007089 1001_ $$0P:(DE-Juel1)131816$$aCoenen, H. H.$$b0$$uFZJ
000007089 245__ $$aFluorine-18 radiopharmaceuticals (beyond [18F]FDG) for use in oncology and neurosciences
000007089 260__ $$aAmsterdam [u.a.]$$bElsevier$$c2010
000007089 29510 $$aReport of an IAEA Consultants Group Meeting
000007089 300__ $$a727 - 740
000007089 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article
000007089 3367_ $$2DataCite$$aOutput Types/Journal article
000007089 3367_ $$00$$2EndNote$$aJournal Article
000007089 3367_ $$2BibTeX$$aARTICLE
000007089 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000007089 3367_ $$2DRIVER$$aarticle
000007089 440_0 $$04644$$aNuclear Medicine and Biology$$v37$$x0883-2897$$y7
000007089 500__ $$aThe Consultants acknowledge the IAEA for its interest and activities in this important field. The authors from the IAEA (MRAP and JJZ) thank Dr. M. Haji-Saeid, Head, Industrial Applications and Chemistry Section, Dr. M. Dondi, Head, Nuclear Medicine Section, and Dr N. Ramamoorthy, Director-NAPC, International Atomic Energy Agency for their support and encouragement.
000007089 520__ $$aPositron emission tomography (PET) is a rapidly expanding clinical modality worldwide thanks to the availability of compact medical cyclotrons and automated chemistry for the production of radiopharmaceuticals. There is an armamentarium of fluorine-18 ((18)F) tracers that can be used for PET studies in the fields of oncology and neurosciences. However, most of the (18)F-tracers other than 2-deoxy-2-[18F]fluoro-D-glucose (FDG) are in less than optimum human use and there is considerable scope to bring potentially useful (18)F-tracers to clinical investigation stage. The International Atomic Energy Agency (IAEA) convened a consultants' group meeting to review the current status of (18)F-based radiotracers and to suggest means for accelerating their use for diagnostic applications. The consultants reviewed the developments including the synthetic approaches for the preparation of (18)F-tracers for oncology and neurosciences. A selection of three groups of (18)F-tracers that are useful either in oncology or in neurosciences was done based on well-defined criteria such as application, lack of toxicity, availability of precursors and ease of synthesis. Based on the recommendations of the consultants' group meeting, IAEA started a coordinated research project on "Development of (18)F radiopharmaceuticals (beyond [(18)F]FDG) for use in oncology and neurosciences" in which 14 countries are participating in a 3-year collaborative program. The outcomes of the coordinated research project are expected to catalyze the wider application of several more (18)F-radiopharmaceuticals beyond FDG for diagnostic applications in oncology and neurosciences.
000007089 536__ $$0G:(DE-Juel1)FUEK409$$2G:(DE-HGF)$$aFunktion und Dysfunktion des Nervensystems (FUEK409)$$cFUEK409$$x0
000007089 536__ $$0G:(DE-HGF)POF2-89572$$a89572 - (Dys-)function and Plasticity (POF2-89572)$$cPOF2-89572$$fPOF II T$$x1
000007089 588__ $$aDataset connected to Web of Science, Pubmed
000007089 650_2 $$2MeSH$$aAnimals
000007089 650_2 $$2MeSH$$aFluorodeoxyglucose F18: diagnostic use
000007089 650_2 $$2MeSH$$aHumans
000007089 650_2 $$2MeSH$$aNeoplasms: radionuclide imaging
000007089 650_2 $$2MeSH$$aNervous System Diseases: radionuclide imaging
000007089 650_2 $$2MeSH$$aRadiopharmaceuticals: diagnostic use
000007089 650_7 $$00$$2NLM Chemicals$$aRadiopharmaceuticals
000007089 650_7 $$063503-12-8$$2NLM Chemicals$$aFluorodeoxyglucose F18
000007089 650_7 $$2WoSType$$aJ
000007089 7001_ $$0P:(DE-HGF)0$$aElsinga, P.H.$$b1
000007089 7001_ $$0P:(DE-HGF)0$$aIwata, R.$$b2
000007089 7001_ $$0P:(DE-HGF)0$$aKilbourn, M.R.$$b3
000007089 7001_ $$0P:(DE-HGF)0$$aPillai, M.R.A.$$b4
000007089 7001_ $$0P:(DE-HGF)0$$aRajan, M.G.R.$$b5
000007089 7001_ $$0P:(DE-HGF)0$$aWagner, H.N.$$b6
000007089 7001_ $$0P:(DE-HGF)0$$aZaknun, J.$$b7
000007089 773__ $$0PERI:(DE-600)1498538-x$$a10.1016/j.nucmedbio.2010.04.185$$gVol. 37, p. 727 - 740$$p727 - 740$$q37<727 - 740$$tNuclear medicine and biology$$v37$$x1872-9614$$y2010
000007089 8567_ $$uhttp://dx.doi.org/10.1016/j.nucmedbio.2010.04.185
000007089 909CO $$ooai:juser.fz-juelich.de:7089$$pVDB
000007089 915__ $$0StatID:(DE-HGF)0010$$aJCR/ISI refereed
000007089 9141_ $$y2010
000007089 9132_ $$0G:(DE-HGF)POF3-572$$1G:(DE-HGF)POF3-570$$2G:(DE-HGF)POF3-500$$aDE-HGF$$bKey Technologies$$lDecoding the Human Brain$$v(Dys-)function and Plasticity$$x0
000007089 9131_ $$0G:(DE-HGF)POF2-89572$$1G:(DE-HGF)POF3-890$$2G:(DE-HGF)POF3-800$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bProgrammungebundene Forschung$$lohne Programm$$v(Dys-)function and Plasticity$$x1
000007089 9201_ $$0I:(DE-Juel1)INM-5-20090406$$gINM$$kINM-5$$lNuklearchemie$$x0
000007089 9201_ $$0I:(DE-82)080010_20140620$$gJARA$$kJARA-BRAIN$$lJülich-Aachen Research Alliance - Translational Brain Medicine$$x1
000007089 970__ $$aVDB:(DE-Juel1)115607
000007089 980__ $$aVDB
000007089 980__ $$aConvertedRecord
000007089 980__ $$ajournal
000007089 980__ $$aI:(DE-Juel1)INM-5-20090406
000007089 980__ $$aI:(DE-82)080010_20140620
000007089 980__ $$aUNRESTRICTED
000007089 981__ $$aI:(DE-Juel1)VDB1046